We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Read MoreHide Full Article
Key Takeaways
IART began building SurgiMend inventory for a phased fourth-quarter 2026 relaunch.
Integra expects SurgiMend share recapture to build gradually, making 2027 the key recovery year.
Integra expects FDA approval earlier in 2027, pending a successful Braintree pre-approval inspection.
Integra LifeSciences Holdings Corp. (IART - Free Report) has begun producing SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. That milestone adds another product-restoration catalyst to the company’s Tissue Reconstruction recovery plan.
The near-term financial effect should be limited. Management assumes no meaningful SurgiMend contribution in 2026, leaving 2027 as the more important period for judging share recapture, regulatory progress and the broader portfolio recovery.
Image Source: Zacks Investment Research
IART’s Braintree Site Starts Building Inventory
Braintree began production in June 2026, giving Integra a manufacturing path to restore SurgiMend after a prolonged disruption. Management is building inventory ahead of a controlled relaunch and expects sufficient supply to support the initial rollout.
The company plans to engage historical high-volume users and key opinion leaders first, applying lessons from the PriMatrix return. Because 2026 guidance includes no meaningful SurgiMend revenues, the current inventory build is more relevant to medium-term portfolio recovery than to this year’s growth.
Integra Expects a Gradual SurgiMend Revenue Return
Management expects SurgiMend share recapture to build over several quarters rather than rebound immediately. On the latest earnings call, it discussed a modest recovery toward roughly 50% of the product’s historical performance of about $40 million, providing a framework for how the relaunch could develop.
That pace makes 2027 central to the investment case. The Zacks Consensus Estimate calls for 2027 revenues of $1.737 billion, up from $1.677 billion in 2026. SurgiMend would be one contributor to that expected growth, but the company has not provided formal 2027 guidance.
Image Source: Zacks Investment Research
IART’s FDA Timeline Remains the Critical Gate
The December 2024 FDA warning letter remains unresolved, and related Class III premarket approvals cannot be approved until the relevant violations are corrected. Integra expects all warning-letter action items to be implemented by the end of 2026, but inspection and approval timing remains under FDA control.
SurgiMend’s clinical safety and efficacy review is complete, and management says an approvable FDA decision is already in place. The remaining premarket approval depends on a successful pre-approval inspection at Braintree, with management expecting approval earlier in 2027.
Integra’s Tissue Portfolio Could Broaden the Recovery
SurgiMend would join a Tissue Reconstruction recovery already supported by DuraSorb growth and the PriMatrix relaunch. Roughly nine months after its return, PriMatrix had recovered slightly more than half of pre-recall revenues and continued to improve sequentially. MediHoney is also expected to return in 2027.
The competitive backdrop remains active. AbbVie Inc. (ABBV - Free Report) markets the AlloDerm Select regenerative tissue matrix for tissue repair and certain post-mastectomy breast reconstruction uses. Becton, Dickinson and Company (BDX - Free Report) offers Phasix Mesh for soft tissue reconstruction. Integra therefore needs product restoration to translate into sustained commercial execution, especially after Tissue Reconstruction revenues declined 2% organically in the second quarter.
IART’s Scores Keep the Relaunch in Perspective
SurgiMend can strengthen Integra’s 2027 recovery path if the relaunch progresses as planned, but the opportunity still depends on gradual customer recapture and successful regulatory execution. The broader Tissue Reconstruction portfolio offers several recovery levers, yet second-quarter performance shows that the segment is not fully back to growth.
IART currently carries a Zacks Rank #3 (Hold). Its Value Score of B is the most supportive Style Score, while the Growth Score of C, VGM Score of C and Momentum Score of D are less favorable. Because Style Scores are designed to complement the Zacks Rank, the current mix supports a measured view of the 2027 catalyst rather than treating the SurgiMend relaunch as a stand-alone buy signal.
View the Zacks #1 Rank List
Image: Bigstock
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Key Takeaways
Integra LifeSciences Holdings Corp. (IART - Free Report) has begun producing SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. That milestone adds another product-restoration catalyst to the company’s Tissue Reconstruction recovery plan.
The near-term financial effect should be limited. Management assumes no meaningful SurgiMend contribution in 2026, leaving 2027 as the more important period for judging share recapture, regulatory progress and the broader portfolio recovery.
Image Source: Zacks Investment Research
IART’s Braintree Site Starts Building Inventory
Braintree began production in June 2026, giving Integra a manufacturing path to restore SurgiMend after a prolonged disruption. Management is building inventory ahead of a controlled relaunch and expects sufficient supply to support the initial rollout.
The company plans to engage historical high-volume users and key opinion leaders first, applying lessons from the PriMatrix return. Because 2026 guidance includes no meaningful SurgiMend revenues, the current inventory build is more relevant to medium-term portfolio recovery than to this year’s growth.
Integra Expects a Gradual SurgiMend Revenue Return
Management expects SurgiMend share recapture to build over several quarters rather than rebound immediately. On the latest earnings call, it discussed a modest recovery toward roughly 50% of the product’s historical performance of about $40 million, providing a framework for how the relaunch could develop.
That pace makes 2027 central to the investment case. The Zacks Consensus Estimate calls for 2027 revenues of $1.737 billion, up from $1.677 billion in 2026. SurgiMend would be one contributor to that expected growth, but the company has not provided formal 2027 guidance.
Image Source: Zacks Investment Research
IART’s FDA Timeline Remains the Critical Gate
The December 2024 FDA warning letter remains unresolved, and related Class III premarket approvals cannot be approved until the relevant violations are corrected. Integra expects all warning-letter action items to be implemented by the end of 2026, but inspection and approval timing remains under FDA control.
SurgiMend’s clinical safety and efficacy review is complete, and management says an approvable FDA decision is already in place. The remaining premarket approval depends on a successful pre-approval inspection at Braintree, with management expecting approval earlier in 2027.
Integra’s Tissue Portfolio Could Broaden the Recovery
SurgiMend would join a Tissue Reconstruction recovery already supported by DuraSorb growth and the PriMatrix relaunch. Roughly nine months after its return, PriMatrix had recovered slightly more than half of pre-recall revenues and continued to improve sequentially. MediHoney is also expected to return in 2027.
The competitive backdrop remains active. AbbVie Inc. (ABBV - Free Report) markets the AlloDerm Select regenerative tissue matrix for tissue repair and certain post-mastectomy breast reconstruction uses. Becton, Dickinson and Company (BDX - Free Report) offers Phasix Mesh for soft tissue reconstruction. Integra therefore needs product restoration to translate into sustained commercial execution, especially after Tissue Reconstruction revenues declined 2% organically in the second quarter.
IART’s Scores Keep the Relaunch in Perspective
SurgiMend can strengthen Integra’s 2027 recovery path if the relaunch progresses as planned, but the opportunity still depends on gradual customer recapture and successful regulatory execution. The broader Tissue Reconstruction portfolio offers several recovery levers, yet second-quarter performance shows that the segment is not fully back to growth.
IART currently carries a Zacks Rank #3 (Hold). Its Value Score of B is the most supportive Style Score, while the Growth Score of C, VGM Score of C and Momentum Score of D are less favorable. Because Style Scores are designed to complement the Zacks Rank, the current mix supports a measured view of the 2027 catalyst rather than treating the SurgiMend relaunch as a stand-alone buy signal.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.